Fig. 9

Upregulation of NAT10 in CRC cells and a schematic model of the UBR5-NAT10-ERRFI1 axis. A. NAT10 expression profiles across colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) tumor samples (in red) and paired normal tissues (in black) based on the GEPIA data resource. B, C. Protein levels of NAT10 determined by IHC in 20 matched CRC tumors and adjacent tissues and quantitative analysis (n = 20). D. Protein levels of NAT10 were detected by IHC and a tissue microarray for 90 patients with CRC. Representative images of the tumor and paired adjacent normal tissues stained with NAT10 are shown. E. Quantitative analysis of IHC staining of NAT10 expression in TMA (n = 90). F. CRC samples were divided into NAT10-high and NAT10-low expression groups according to the median expression of NAT10; Kaplan–Meier survival analysis showed that the upregulation of NAT10 was significantly associated with a poor overall survival rate. G. Kaplan–Meier analysisof PPS for patients with CRC based on NAT10 expression using the online tool Kaplan–Meier Plotter (Up: KRAS mutated type; Down: KRAS wild type). H. Schematic of the UBR5-NAT10-ERRFI1 axis. The data are representative of three independent experiments and presented as the mean ± SD. *P < 0.05, ****P < 0.0001, determined using two-tailed unpaired Student’s t-tests